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           One of the characteristics of type 2 diabetes mellitus (T2DM) is the state 
of persistent oxidative stress (OS) that has been implicated in the pathogenesis 
of diseases such is atherosclerosis mainly through chronic hyperglycemia that 
stimulates production of reactive oxygen species (ROS) and increases OS.  
Glutathione S-transferase P1 (GSTP1) is a  member  of  the cytosolic 
GST superfamily. It plays an important role in neutralizing OS as an enzyme. 
Also, it participates in regulation of stress signaling and protects cells against 
apoptosis  via  its  noncatalytic  ligand-binding  activity.  GSTP1  Ile105Val 
functional polymorphism influences protein catalytic activity and stability and 
the aim of this study was to determine whether this gene variation influences 
susceptibility to atherogenesis in T2DM patients.  
A total of 240 individuals (140 patients with T2DM, accompanied with 
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included in this study. Genomic DNA was isolated from peripheral blood cells 
and genotyping was performed using polymerase chain reaction followed by 
restriction fragment length polymorphism (PCR-RFLP) analysis.  
We obtained no statistically significant differences in the distribution of alleles 
and genotypes between cases and controls (P>0.05) but association between 
Ile/Val (OR=0.6, 95%CI=0.35-1.05, P=0.08) and Val/Val (OR=0.45, 
95%CI=0.18-1.11, P=0.08) genotypes and disease approached significance 
(P=0.08).  
Our results indicated that a larger study group is needed to establish the true 
relationship between potentialiy protective allele Val and the disease, and to 
determine the  influence  of  other  GSTP1 polymorphisms  on  atherogenesis in 
T2DM patients. 
Key words: GlutathioneS-transferase P1, gene polymorphism, type 2 
diabetes mellitus, atherosclerosis 
 
INTRODUCTION 
Diabetes is one of the most frequent chronic diseases and it is a major public health 
problem worldwide. Serbia belongs to the group of European countries with the highest diabetes 
mortality rates where diabetes is the fifth leading cause of death and the fifth cause of the burden 
of disease. The number of deaths is even higher because of the errors in coding the causes of 
death particulary in those who died from myocardial infarction, stroke or other microvascular 
and macrovascular long term comlications. At least a half of the persons, especially elderly, with 
type 2 diabetes mellitus (T2DM) have not been diagnosed and are not aware of their disease  
until mainly cardiovascular and renal complications are already present (INSTITUTE OF PUBLIC 
HEALTH OF SERBIA "DR MILAN JOVANOVIĆ BATUT, 2011). Diabetes prevalence grows with age 
and ageing is associated with decrease in insulin secretion, action and clearance even in non-
obese healthy elderly subjects (STEVIC et al. 2007). 
As the result of diabetes there is a state of increased oxidative stress (OS) that leads to 
the  development  of  accelerated  atherosclerosis.  Chronic  hyperglycemia  stimulates  reactive 
oxygen species (ROS) production and increases oxidative stress. Excessive generation of ROS, 
such as superoxide, hydrogen peroxide and hydroxyl radical, along with reactive nitrogen species 
(RNS) such as nitric oxide, oxidize DNA, proteins and other cellular components leading to their 
damage (PITOCCO et al. 2010; KANETO et al. 2010; PEREIRA et al. 2008). Studies have shown that 
individuals  with  lowered  antioxidant  capacity  are  at  increased  risk  of  T2DM  (BAYNESS  and 
THORPE, 1999; GALLOU et al. 1993).  
Among candidate genes related to OS, genes for cytosolic glutathione S-transferases 
(GSTs),  especially  mu  (GSTM1),  theta  (GSTT1)  and  pi  (GSTP1)  are  intensively  studied. 
Although these cytosolic GSTs detoxify cytotoxic agents and protect cellular macromolecules 
catalyzing the conjugation of electrophilic compounds with glutathione (GSH), the role of GSTs 
in catalyzing the conjugation with endogenous products of oxidative damage to lipids (acrolin, 
crotonaldehyde, 4-hydroxynonenal) and DNA (base propenals) is well established (BERHANE et 
al.  1994).  At  physiological  concentrations,  GSTs  regulate  ROS  levels  influencing  cellular 
proliferation  and  preventing  ROS  accumulation  (HAYES  and  MCLELLAN,  1999)  and  thereby 
every change in GSTs genes can lead to oxidative stress.  I. GRUBISA et al: GSTP1 POLYMORPHISM IN T2DM RELATED ATHEROSCLEROSIS                             229 
 
Glutathion S-transferase P1 (GSTP1) is a member of the cytosolic GST superfamily 
(COWELL  et  al.  1988;  MANNERVIK  and  DANIELSON,  1988).  Because  of  its  enzymatic  and 
nonenzymatic multiple roles (WANG et al. 2001; HOLLEY et al. 2007) variation in the expression 
and activity of GSTP1 has been associated with a variety of human diseases (HARRIES et al.1997; 
MATTHIAS et al. 1998; MCILWAIN et al. 2006; NIKOLIĆ et al. 2011; SUVAKOV et al. 2012; AMER et 
al. 2012; GÖNÜL et al. 2012; KARIŽ et al. 2012; SANTL  LETONJA et al. 2012; GRUBISA et al. 
2012). 
GSTP1 is genetically polymorphic and two common nonsynonymous single nucleotide 
polymorphisms (SNPs) (Ile105Val and Ale114Val) and the methylation state of a CpG islands in 
its  promoter  have  been  studied  extensively.  The  Ile105Val  genotype  constitutes  an  A313G 
change causing an Ile to Val substitution at amino acid 105 within the active site of the enzyme 
which  results  in  substantial  reduction  of  enzyme  activity  by  altering  its  catalytic  activity 
(TOWNSEND and TEW, 2003).  
Since the susceptibility to OS is partially determined by genetic background there has 
been a deep interest in discovering additional genetic variants as markers of OS, which may have 
a role in predicting risk of oxidative stress-based diseases. So, in the present study we have 
evaluated  possible  interactions  between  GSTP1  Ile105Val  gene  polymorphism  and  clinical 
manifestations of atherosclerosis in type 2 diabetes mellitus patients from Serbia. 
 
MATERIALS AND METHODS 
The  study  comprised  of  140  patients  with  T2DM  and  clinical  manifestations  of 
atherosclerosis (86 males and 54 females, age 40-70 years) treated at Dedinje Cardiovascular 
Institute and Zvezdara University Medical Center, Belgrade, Serbia from 2010-2011. The control 
group was composed of 100 healthy individuals, age and sex matched with cases. Participants 
were not related and originated from different parts of Serbia and only those who have signed the 
informed  consent  have  been  included  in  the  study.  The  study  was  approved  by  the  ethical 
Committee of Zvezdara University Medical Center.  
All patients had diagnostic criteria for diabetes based on subsequent values of glycemia 
(2 values of glycemia in 2 subsequent days): fasting plasma glucose concentration ≥7,0 mmol/L 
(126 mg/dL) or glycemia in any random blood sample (regardless of meals) ≥ 11,1 mmol/L (200 
mg/dL) with the presence of typical diabetes symptoms (polyuria, polydipsia, weight loss) or 
based on the value of glycemia during an Oral Glucose Tolerance Test (OGTT): plasma glucose 
concentration during an OGTT in the 120th minute ≥ 11,1mmol/L (200 mg/dL) ((INSTITUTE OF 
PUBLIC HEALTH OF SERBIA "DR MILAN JOVANOVIĆ BATUT, 2011). Diagnosis of atherosclerosis was 
based on medical and familiy history, physical exam, blood test and some of noninvasive and 
invasive  test-methods  (echocardiogram,  ankle/brachial  index,  stress  testing,  computed 
tomography scan, angiography) or according to anamnesis data about: lower extremity arterial 
surgery,  carotid  artery  surgery,  previous  myocardial  infarction,  previous  cerebro-vascular 
diseases, vascular dementia, angina.  
Genomic DNA was extracted from peripheral blood cells by DNeasy Blood & Tissue 
Kit (Qiagen, GmbH, Germany), and isolated DNA was stored at +4 °C until further analysis. 
GSTP1  Ile105Val  genotyping  was  performed  using  polymerase  chain  reaction-
restriction  fragment  length  polymorphism  (PCR-RFLP)  method  as  previously  described 
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Fermentas, Lithuania) according to manufacturers recommendations. Digestion products were 
separated on 3 % agarose gel, stained with ethidium bromide (0.5 µg/mL) and visualized under 
UV light for genotype determination. The absence of restriction site indicated wild type (WT) 
genotype Ile/Ile (176bp), and presence of restriction site resulting in two fragments 91bp and 85 
bp indicated mutant genotype Val/Val. 
Statistical  analysis  was  carried  out  using  SPSS  software  (version  17).  Allele  and 
genotype frequencies in cases and controls were compared using chi-square test (Χ
2 test) and the 
risk of disease was assessed using logistic regression analysis. A P value <0.05 was considered 
significant. 
 
RESULTS 
The allele and genotype frequency distribution for the GSTP1 Ile105Val polymorphism in 
T2DM patients with clinical manifestations of atherosclerosis and controls are given in Table 1.  
Low-activity (Val) allele was more frequent in the control group (38.5%) compared to 
cases (32%) and heterozygotes Ile/Val and homozygotes Val/Val genotypes frequencies were 
higher  in  controls  than  in  patients  (55%  versus  45%  for  Ile/Val  and  11%  versus  9.3%  for 
Val/Val), the difference however did not reach statistical significance between groups (P>0.05).  
Similarly, none of the values obtained by logistic regression analysis showed a statistical 
significance  though  Val  allele  (OR=0.7,  95%CI=0.5-1.8,  P=0.13),  Ile/Val  (OR=0.6, 
95%CI=0.35-1.05,  P=0.08)  and  Val/Val  (OR=0.45,  95%CI=0.18-1.11,  P=0.08)  genotypes 
showed  1.43,  1.67  and  2.22  fold  decrease  in  risk  of  disease,  respectively.  Also,  grouped 
genotypes  Ile/Val+Val/Val  showed  a  nonsignificant  1.37  fold  decrease  in  risk  (OR=0.73, 
95%CI=0.43-1.25, P=0.26) in compare with reference Ile/Ile (Table 1). 
 
Table 1. The genotype and allele frequencies and logistic regression analysis of GSTP1 Ile105Val gene 
polymorphism 
  Cases 
(140) 
Controls 
(100) 
OR  95%CI  P-value 
Genotype frequency, N (%) 
Ile/Ile 
Ile/Val 
Val/Val 
Ile/Val+Val/Val 
 
64 (45.7) 
63 (45) 
13 (9.3) 
76 (54.3) 
 
34 (34) 
55 (55) 
11 (11) 
66 (66) 
 
1.00 
0.6 
0.45 
0.73 
 
Standard 
0.35-1.05 
0.18-1.11 
0.43-1.26 
 
 
0.08 
0.08 
0.26 
Allele frequency, n (%) 
Ile 
Val 
 
191 (68) 
 89 (32) 
 
123 (61,5) 
 77 (38.5) 
 
1.00 
0.7 
 
Standard 
0.5-1.8 
 
 
0.13 
 
DISCUSSION 
The  most  of  diabetes-related  deaths  and  complications  are  due  to  cardiovascular 
diseases. As a result of diabetes, there is a state of increased oxidative stress and compromised 
antioxidant  defense  that  leads  to  the  development  of  accelerated  atherosclerosis  and  both 
microvascular and macrovascular long-term complications.  I. GRUBISA et al: GSTP1 POLYMORPHISM IN T2DM RELATED ATHEROSCLEROSIS                             231 
 
Excess mortality from coronary heart disease (CHD) among diabetic people compared 
to the general population has been demonstrated (HUXLEY et al. 2006). Cross-sectional study of 
657 consecutive patients with symtomatic carotid atherosclerotic disease from our population 
showed that half of these patients have features of the metabolic syndrome (55.6% of studied 
patients) (MAKSIMOVIC et al. 2009). Patients with premature atherosclerosis (≤ 50 years of age) 
more frequently had 4 and 5 risk factors for atheosclerosis and DM is among the most significant 
for atherosclerotic disease of the supra-aortic branches. In patients with coronary artery disease 
(CAD), DM is a less prevalent risk factor in patients with premature coronary disease compared 
with elderly (RADAK et al. 2012). 
In  the  present  case-control  study  we  have  investigated  the  association  of  GSTP1 
Ile105Val with cardiovascular complications in state of increased oxidative stress. According to 
our  results  there  are  no  statistically  significant  differences  in  the  distribution  of  alleles  and 
genotypes  for  the  GSTP1  Ile105Val  polymorphism  between  cases  and  controls,  which  is  in 
accordance with the results of some other similar studies (GÖNÜL et al. 2012; SANTL LETONJA et 
al. 2012; KARIŽ et al. 2012; MOASSER et al. 2012).  
Though this GSTP1 gene polymorphism has been widely studied in malignant diseases 
and many previous studies reported the association between Val with a variety of human cancers 
(HARRIES  et  al.1997;  MATTHIAS  et  al.  1998;  MCILWAIN  et  al.  2006;  NIKOLIĆ  et  al.  2011), 
controversial results have been reported so far about the importance of this allele in oxidative 
stress-based diseases (FRYER et al. 2000; MATTEY et al. 1999; ISHII et al. 1999; MANN et al. 2000; 
SUVAKOV et al. 2012; AMER et al. 2012; GÖNÜL et al. 2012; KARIŽ et al. 2012; SANTL LETONJA et 
al. 2012; RAMPRASATH et al. 2011; BID et al. 2010; GRUBISA et al. 2012).  
The  controversial  results  obtained  by  studies  of  different  populations  might  be 
atribbuted  to  the  interaction  of  many  factors,  such  as  differences  in  ethnic  background  and 
differential susceptibility to diseases. Our study confirmed previously reported results from other 
studies from Serbia reporting effects of GSTP1 Ile105Val polymorphism on T2DM in patients 
with  pancreatic  disease  (NIKOLIĆ et al.  2011),  on  oxidative  stress in  haemodialysis  patients, 
including  patients  with  diabetic  nephropathy  (SUVAKOV  et  al.  2012),  and  effects  of  this 
polymorphism on patients with clinical manifestations of atherosclerotic disease without T2DM 
(GRUBISA et al. 2012).  
Our results showed statistically nonsignificant decrease in the risk of atherosclerosis for 
allele Val and genotypes Ile/Val and Val/Val, but the association between these two genotypes 
and disease approached significance (P=0.08). Similar results have been reported in patients with 
manifest atherosclerotic disease (GRUBISA et al. 2012) and in the study on rheumatoid arthritis 
(MATTEY et al. 1999). In a study performed by Fryer and coworkers (FRYER et al. 2000), authors 
found  that  the  Val1/Val  genotype  conferred  a  6-fold  decrease  in  asthma  risk  and  that  this 
genotype correlated with decreased severity of airway hyperresponsiveness (AHR). Mann et al 
(MANN et al. 2000) found that GSTM3 AA and homozygosity for both GSTM1*0 and the GSTP1 
Ile were linked with severe disability in multiple sclerosis (MS) and association between Ile and 
chronic obstructive pulmonary disease (COPD) was also found (ISHII et al. 1999).  
GSP1 performs as a phase II detoxification enzyme. Also, it participates in regulation of 
stress signaling and protects cell against apoptosis via its noncatalytic ligand-binding activity 
(HOLLEY et al. 2007). In low levels of OS or unstressed conditions GSTP1 is found catalytically 
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higher  levels  of  OS  causes  GSTP1  dissociation  from  GSTP1-JNK  complexes  and  JNK 
activation.  This  activates  signalling  pathways  for  stress response  and  apoptosis,  and  GSTP1 
forms  covalently  linked  and  enzymatically  inactive  dimers  and  oligomers  (TEW  and  RONAI, 
1999).  Some  studies  suggested  that  suppression  of  GSTP1  leads  to  elevated  JNK  activity, 
increased proliferation and reduced apoptosis (RUSCOE et al. 2001). Also, oxidative stress causes 
activation of transcription factor nuclear factor-kappa B (NF-kB) that induces expression of NF-
kB  responsive  genes  including  GSTP1  (XIA  et  al.  1996),  while  GSTP1  expression  rises  in 
response to OS or proinflammatory stimuli. 
When  the  expression  of  GSTP1  decreases  or  protein  has  low  activity,  it  has  been 
speculated that cell becomes more susceptible to mutation and damage as a result of exposure to 
electrophiles and oxidative stress (KINZLER and VOGELSTEIN, 1997). It has been assumed that 
genetic variation is responsible for alteration in the level of enzyme activity as a result of at least 
two mechanisms-changes in the active site (Ile to Val substitution in the hydrophobic substrate 
binding  site),  and  differences  in  levels  of  enzyme  protein  (MOYER  et  al.  2008).  Probably, 
alteration of only one or two amino acids as a result of genetic polymorphism can be associated 
with drastic changes in the level of protein often due to rapid protein degradation through a 
ubiquitin-proteasome-mediated process (WANG et al. 2003; WEINSHILBOUM and WANG, 2004). In 
studies on GSTP1 gene sequence variation and functional genomic, about 35 SNPs have been 
identified and some of them are uncaracterized yet. Authors showed that the variant nucleotide at 
(-18) resulted in protein binding that was not observed in WT sequence. Because this functional 
SNP is tighly linked with Ile105Val it is possible that a portion of the association of the codon 
105 polymorphism with various clinical phenotypes may result from the effect of transcription of 
G(-18)A  SNP  (MOYER  et  al.  2008).  We  evaluated  only  one  polymorphism  in  polymorphic 
GSTP1 that probably limited this association study. 
Although our data provide evidence that Ile105Val polymorphism is not associated with 
increased oxidative stress in T2DM and atherogenesis, a larger study group is needed to establish 
true relationship between potentialy protective allele Val and individual susceptibility to disease 
in our population. Also, study on other GSTP1 gene polymorphisms is recommended. 
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Izvod 
Jedna od osobina tipa 2 dijabetes mellitus (T2DM) je stanje perzistentnog oksidativnog 
stresa (OS) koji je sastavni deo patogeneze bolesti kao što je ateroskleroza i to najčešće putem 
hronične hiperglikemije koja stimuliše nastanak reaktivnih vrsta kiseonika (tzv ROS) i povećava 
nivo OS.  
  Glutation S-transferaza P1 (GSTP1) pripada superfamiliji citosolnih GST. Kao enzim, 
ima važnu ulogu u neutralizaciji OS. Takođe, učestvuje u regulaciji signalnog puta stresa ali i 
štiti  ćelije  od  apoptoze  putem  nekatalitičke  ligand-vezujuće  aktivnosti.  Funkcionalni 
polimorfizam  Ile105Val  GSTP1  gena  utiče  na  katalitičku  aktivnost  proteina  i  na  njegovu 
stabilnost i cilj ove studije je bio da se utvrdi da li ova genska varijanta utiče na osetljivost na 
aterogenezu kod pacijenata sa T2DM.  
Ukupno  240  osobe  (140  pacijenata  sa  T2DM  i  nekom  od  kliničkih  manifestacija 
ateroskleroze  i  100  zdravih  kontrola)  je  bilo  uključeno  u  ovu  studiju.  Genomska  DNK  je 
izolovana  iz  ćelija  periferne  krvi  a  genotipizacija  je  urađena  primenom  reakcije  lančane 
polimeraze posle koje je urađena analiza dužine restrikcionih fragmenata (PCR-RFLP analiza). 
Nismo dobili statistički značajne razlike u raspodeli alela i genotipova između obolelih i 
kontrola (P>0.05) ali asocijacija između Ile/Val (OR=0.6, 95%CI=0.35-1.05, P=0.08) i Val/Val 
(OR=0.45, 95%CI=0.18-1.11, P=0.08) genotipova i bolesti se približila značajnosti (P=0.08). 
Naši rezultaati pokazuju da je potrebna veća grupa ispitanika da bi se utvrdila prava 
veza između potencijalno protektivnog alela Val i bolesti kao i da bi se utvrdio uticaj drugih 
polimorfizama gena GSTP1 na aterogenezu kod T2DM pacijenata. 
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